Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Finished Goods (2016 - 2025)

Historic Finished Goods for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $8.6 million.

  • Corcept Therapeutics' Finished Goods rose 685.71% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 685.71%. This contributed to the annual value of $8.2 million for FY2024, which is 600.7% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Finished Goods of $8.6 million as of Q3 2025, which was up 685.71% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Finished Goods registered a high of $9.2 million during Q4 2022, and its lowest value of $4.9 million during Q3 2021.
  • Moreover, its 5-year median value for Finished Goods was $7.5 million (2023), whereas its average is $7.2 million.
  • Its Finished Goods has fluctuated over the past 5 years, first plummeted by 2509.32% in 2021, then skyrocketed by 4894.88% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Finished Goods (Quarter) stood at $6.5 million in 2021, then soared by 41.6% to $9.2 million in 2022, then fell by 15.9% to $7.7 million in 2023, then increased by 6.01% to $8.2 million in 2024, then grew by 4.83% to $8.6 million in 2025.
  • Its Finished Goods stands at $8.6 million for Q3 2025, versus $6.7 million for Q2 2025 and $8.5 million for Q1 2025.